Pain Medication Safety for Elderly PI Patients

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 8 min read

Elderly personal injury patients face amplified medication risks due to age-related pharmacokinetic changes, polypharmacy from pre-existing conditions, and Beers Criteria restrictions. This guide covers geriatric-specific drug safety considerations and documentation implications for PI cases.

Elderly patients (age 65 and older) in personal injury cases face fundamentally different medication safety profiles than younger adults due to age-related changes in drug metabolism, renal function, hepatic capacity, body composition, and CNS sensitivity. These physiological changes make standard PI medication doses more potent, more toxic, and more likely to produce adverse effects -- requiring geriatric-specific dosing, monitoring, and medication selection that adds measurable treatment complexity to the PI case.

• Age-related decline in renal function (GFR decreases approximately 1 mL/min/year after age 40) reduces clearance of renally eliminated medications, prolonging drug exposure and increasing toxicity risk
• Decreased hepatic blood flow and Phase I metabolism (CYP450 capacity) slows metabolism of opioids, benzodiazepines, and other hepatically cleared PI medications
• Increased body fat percentage and decreased lean mass and total body water alter drug distribution -- fat-soluble drugs (benzodiazepines, fentanyl) accumulate while water-soluble drugs reach higher plasma concentrations
• The Beers Criteria list of potentially inappropriate medications for older adults restricts many standard PI medications, requiring alternative selections that document geriatric-specific treatment complexity
• LienScripts applies geriatric pharmacology screening to all patients age 65+ through its pharmacy lien program

Pharmacokinetic Changes in Aging

Absorption

GI absorption is generally preserved in aging, but decreased gastric acid production and slowed GI motility can delay absorption onset for some medications. The clinical impact on PI medications is modest compared to distribution, metabolism, and elimination changes.

Distribution

Increased body fat: Body fat percentage increases from approximately 18-36% (male) and 33-48% (female) between ages 25 and 75. Fat-soluble medications (benzodiazepines, fentanyl, trazodone) accumulate in the expanded fat compartment, producing a larger volume of distribution and prolonged elimination half-life. Diazepam's half-life, for example, extends from approximately 24 hours in a 20-year-old to 80-100 hours in an 80-year-old.

Decreased albumin: Serum albumin declines with age, reducing protein binding of highly protein-bound drugs (naproxen, diazepam, warfarin). The unbound (active) fraction increases, producing more intense pharmacological effect at the same total plasma concentration.

Decreased total body water: Water-soluble drugs (morphine, acetaminophen, gabapentin) distribute into a smaller water compartment, producing higher peak plasma concentrations.

Metabolism

Hepatic blood flow decreases 20-40% with aging, reducing first-pass metabolism of oral medications. CYP450 Phase I oxidative metabolism capacity declines, while Phase II conjugation (glucuronidation) is relatively preserved. This has direct implications for PI medications:

• Oxycodone and hydrocodone (CYP3A4/2D6 substrates): Slower metabolism produces higher and more prolonged plasma levels
• Benzodiazepines metabolized by oxidation (diazepam, alprazolam): Extended half-lives; lorazepam and oxazepam are preferred in elderly because they undergo Phase II glucuronidation only
• Cyclobenzaprine (hepatically metabolized): Extended half-life increases anticholinergic burden

Elimination

Renal function declines predictably with aging. The average 80-year-old has approximately 50% of the GFR of a 30-year-old. This affects renally cleared PI medications:

• Gabapentin and pregabalin: 100% renal elimination; dose must be reduced proportionally to GFR
• Morphine-6-glucuronide (active metabolite of morphine): Accumulates in renal impairment, producing prolonged analgesia and respiratory depression risk
• NSAIDs: Reduced renal prostaglandin production in elderly + NSAID-mediated prostaglandin inhibition = compounded renal risk

The Beers Criteria: Medications to Avoid

The American Geriatrics Society Beers Criteria identify medications that are potentially inappropriate for patients 65 and older. Several standard PI medications appear on this list:

Avoid in All Elderly Patients

• Long-acting benzodiazepines (diazepam, clonazepam): Increased sensitivity to CNS depression, prolonged half-life, fall and fracture risk
• Non-benzodiazepine hypnotics (zolpidem): Fall risk, cognitive impairment, minimal benefit over placebo in elderly
• Skeletal muscle relaxants (cyclobenzaprine, methocarbamol, carisoprodol): Anticholinergic effects, sedation, fall risk; efficacy questionable in elderly
• Indomethacin: Highest CNS adverse effect risk among NSAIDs; cognitive impairment, GI bleeding
• Meperidine: Neurotoxic metabolite normeperidine accumulates; seizure risk

Use with Caution in Elderly

• Opioids generally: Fall risk, cognitive impairment, respiratory depression; start at 25-50% of standard adult dose
• NSAIDs: GI bleeding risk increases with age; use lowest effective dose for shortest duration; GI prophylaxis (PPI) recommended
• Gabapentin/pregabalin: Dose adjustment for renal function; fall risk from sedation and ataxia

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "The Beers Criteria exist because the standard adult dosing that works safely in a 35-year-old patient can produce falls, cognitive impairment, and hospital admissions in an 80-year-old patient receiving the same medication at the same dose. Every PI medication decision in an elderly patient involves a geriatric-specific risk assessment."

Fall Risk: The Compounding Danger

Falls are the leading cause of injury death in adults 65 and older. Multiple PI medications increase fall risk:

• Opioids: Sedation, dizziness, orthostatic hypotension
• Benzodiazepines: Impaired balance, psychomotor slowing, muscle relaxation
• Muscle relaxants: Sedation, weakness, anticholinergic dizziness
• Gabapentin/pregabalin: Dizziness, ataxia, peripheral edema affecting balance
• Trazodone: Orthostatic hypotension, sedation

For an elderly PI patient already recovering from a fall-related injury, these medications create a paradox: the injury requires pain management that increases the risk of another fall. Documenting this paradox and the medication management strategies employed to mitigate it (lower doses, fall prevention counseling, medication timing adjustments) adds treatment complexity documentation to the case.

Polypharmacy: Pre-Existing Medication Burden

Elderly patients typically enter PI treatment with existing medication regimens for chronic conditions:

• Cardiovascular: Antihypertensives (ACE inhibitors, beta-blockers), anticoagulants (warfarin, apixaban), statins
• Diabetes: Metformin, insulin, sulfonylureas
• Osteoporosis: Bisphosphonates, calcium, vitamin D
• GI: Proton pump inhibitors, H2 blockers

Each pre-existing medication creates potential drug interactions with PI medications. The "triple whammy" of NSAID + ACE inhibitor + diuretic producing acute kidney injury is a classic geriatric drug interaction that occurs when an NSAID is added for injury pain to an elderly patient already on cardiovascular medications.

Documentation Value for PI Cases

Geriatric-Specific Treatment Complexity

The need for geriatric dosing, Beers Criteria compliance, renal function-based dose adjustment, and fall risk mitigation documents treatment complexity that goes beyond standard PI pharmaceutical care.

Amplified Injury Impact

An injury that would require straightforward medication management in a younger patient requires careful, monitored, dose-adjusted management in an elderly patient. This amplified treatment complexity documents greater injury impact.

Higher Adverse Event Risk

The elevated risk of adverse drug events (falls, cognitive impairment, renal injury, GI bleeding) in elderly patients documents the ongoing medical risk that the accident-related medication creates -- a risk that would not exist without the accident.

LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages. For elderly patients, the MERIT includes Beers Criteria screening results, geriatric dose adjustments, drug interaction screening against pre-existing medications, and fall risk assessments -- creating a comprehensive geriatric pharmaceutical care record.

What PI Attorneys Should Know

Every elderly PI patient's medication record should be evaluated through a geriatric pharmacology lens. A medication regimen that appears unremarkable in a younger patient may represent significant clinical complexity and risk in an elderly patient. The LienScripts clinical pharmacy team applies this geriatric lens automatically, ensuring that the documentation captures the true scope of pharmaceutical care required for the elderly PI population.